Cayron Coralie, Guillermet-Guibert Julie
Inserm U1037, CRCT, Université Toulouse III Paul Sabatier, 2 av Hubert Curien, 31037 Toulouse, France; Laboratoire d'Excellence ANR-Toucan, Toulouse, France.
Inserm U1037, CRCT, Université Toulouse III Paul Sabatier, 2 av Hubert Curien, 31037 Toulouse, France; Laboratoire d'Excellence ANR-Toucan, Toulouse, France.
Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101473. doi: 10.1016/j.clinre.2020.05.021. Epub 2020 Jun 24.
Pancreatic ductal adenocarcinoma PDAC is a complex disease with an important diversity of genetic alterations found between patients. KRAS mutation is considered as a major oncogenic driver in this cancer (around 90% of the patients), but there exists different KRAS mutation types. The type of KRAS mutation was recently shown to be of importance to detect signalling vulnerabilities in a subset of PDAC patients. We comment on these innovative results and discuss their importance when designing clinical trials with PI3K targeted therapies in this cancer.
胰腺导管腺癌（PDAC）是一种复杂的疾病，患者之间存在重要的基因改变多样性。KRAS突变被认为是这种癌症的主要致癌驱动因素（约90%的患者），但存在不同的KRAS突变类型。最近研究表明，KRAS突变类型对于检测一部分PDAC患者的信号脆弱性具有重要意义。我们对这些创新性结果进行评论，并讨论在设计针对这种癌症的PI3K靶向治疗的临床试验时它们的重要性。
